Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Arbutus Biopharma (Nasdaq: ABUS) announced significant leadership changes, appointing Lindsay Androski as Chief Executive Officer, replacing Interim President and CEO Michael J. McElhaugh, effective immediately. Androski, an MIT-trained biologist with nearly 30 years of experience in biotechnology, law, and academia, will also join the company's board of directors.
The clinical-stage biopharmaceutical company has also appointed four new directors to its board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline, and Anuj Hasija. All previous board members have stepped down, reducing the board to five members total. The company may consider adding directors with clinical development expertise in the coming months.
Androski stated that these leadership changes aim to enable "renewed focus on advancing the company's pipeline efficiently and maximizing the company's contributions to LNP delivery technology through Genevant." The company will temporarily pause investor meetings while the new leadership reviews development plans and strategic options for its hepatitis B programs.
Arbutus Biopharma (Nasdaq: ABUS) ha annunciato significative modifiche nella leadership, nominando Lindsay Androski come Amministratore Delegato, che sostituisce il Presidente e CEO ad interim Michael J. McElhaugh, con effetto immediato. Androski, biologa formata al MIT con quasi 30 anni di esperienza nei settori della biotecnologia, del diritto e dell'accademia, entrerà anche a far parte del consiglio di amministrazione dell'azienda.
La società biofarmaceutica in fase clinica ha anche nominato quattro nuovi membri nel suo consiglio: Robert Alan Beardsley, Joseph Bishop, Matthew Gline e Anuj Hasija. Tutti i membri precedenti del consiglio si sono dimessi, riducendo il consiglio a un totale di cinque membri. L'azienda potrebbe considerare di aggiungere direttori con esperienza nello sviluppo clinico nei prossimi mesi.
Androski ha dichiarato che queste modifiche nella leadership mirano a consentire un "rinnovato focus sull'avanzamento del pipeline dell'azienda in modo efficiente e a massimizzare i contributi dell'azienda alla tecnologia di somministrazione LNP attraverso Genevant." L'azienda sospenderà temporaneamente gli incontri con gli investitori mentre la nuova leadership rivede i piani di sviluppo e le opzioni strategiche per i suoi programmi contro l'epatite B.
Arbutus Biopharma (Nasdaq: ABUS) anunció cambios significativos en su liderazgo, nombrando a Lindsay Androski como Directora Ejecutiva, reemplazando al Presidente y CEO interino Michael J. McElhaugh, con efecto inmediato. Androski, bióloga formada en el MIT con casi 30 años de experiencia en biotecnología, derecho y academia, también se unirá a la junta directiva de la empresa.
La compañía biofarmacéutica en etapa clínica también ha nombrado a cuatro nuevos directores en su junta: Robert Alan Beardsley, Joseph Bishop, Matthew Gline y Anuj Hasija. Todos los miembros anteriores de la junta han renunciado, reduciendo la junta a un total de cinco miembros. La empresa podría considerar la adición de directores con experiencia en desarrollo clínico en los próximos meses.
Androski declaró que estos cambios en el liderazgo tienen como objetivo permitir un "nuevo enfoque en avanzar la cartera de la empresa de manera eficiente y maximizar las contribuciones de la empresa a la tecnología de entrega de LNP a través de Genevant." La empresa pausará temporalmente las reuniones con inversores mientras el nuevo liderazgo revisa los planes de desarrollo y las opciones estratégicas para sus programas de hepatitis B.
Arbutus Biopharma (Nasdaq: ABUS)는 주요 리더십 변화를 발표하며 Lindsay Androski를 CEO로 임명하고, Michael J. McElhaugh 임시 CEO를 즉시 대체한다고 밝혔습니다. MIT에서 생물학을 전공한 Androski는 생명공학, 법률 및 학계에서 거의 30년의 경험을 보유하고 있으며, 회사의 이사회에도 합류할 예정입니다.
임상 단계의 생물 의약품 회사는 이사회에 네 명의 새로운 이사를 추가로 임명했습니다: Robert Alan Beardsley, Joseph Bishop, Matthew Gline 및 Anuj Hasija. 모든 이전 이사들이 사임하여 이사 수가 총 5명으로 줄어들었습니다. 회사는 향후 몇 달 내에 임상 개발 전문성을 가진 이사를 추가하는 것을 고려할 수 있습니다.
Androski는 이러한 리더십 변화가 "회사의 파이프라인을 효율적으로 발전시키고 Genevant를 통한 LNP 전달 기술에 대한 회사의 기여를 극대화하는 데 새롭게 집중할 수 있도록" 하기 위한 것이라고 밝혔습니다. 회사는 새로운 리더십이 B형 간염 프로그램에 대한 개발 계획과 전략적 옵션을 검토하는 동안 투자자 회의를 일시적으로 중단할 것입니다.
Arbutus Biopharma (Nasdaq: ABUS) a annoncé des changements significatifs dans sa direction, nommant Lindsay Androski au poste de Directrice Générale, remplaçant le Président et CEO par intérim Michael J. McElhaugh, avec effet immédiat. Androski, biologiste formée au MIT avec près de 30 ans d'expérience en biotechnologie, droit et académique, rejoindra également le conseil d'administration de l'entreprise.
L'entreprise bio-pharmaceutique en phase clinique a également nommé quatre nouveaux administrateurs à son conseil : Robert Alan Beardsley, Joseph Bishop, Matthew Gline et Anuj Hasija. Tous les membres précédents du conseil ont démissionné, réduisant le conseil à un total de cinq membres. L'entreprise pourrait envisager d'ajouter des administrateurs ayant une expertise en développement clinique dans les mois à venir.
Androski a déclaré que ces changements de leadership visent à permettre un "nouveau focus sur l'avancement efficace du pipeline de l'entreprise et à maximiser les contributions de l'entreprise à la technologie de livraison LNP à travers Genevant." L'entreprise suspendra temporairement les réunions avec les investisseurs pendant que la nouvelle direction examine les plans de développement et les options stratégiques pour ses programmes de lutte contre l'hépatite B.
Arbutus Biopharma (Nasdaq: ABUS) hat bedeutende Veränderungen in der Unternehmensführung angekündigt und Lindsay Androski zur Geschäftsführerin ernannt, die den interimistischen Präsidenten und CEO Michael J. McElhaugh sofort ersetzt. Androski, eine am MIT ausgebildete Biologin mit fast 30 Jahren Erfahrung in Biotechnologie, Recht und Wissenschaft, wird auch dem Vorstand des Unternehmens beitreten.
Das biopharmazeutische Unternehmen in der klinischen Phase hat außerdem vier neue Direktoren in seinen Vorstand berufen: Robert Alan Beardsley, Joseph Bishop, Matthew Gline und Anuj Hasija. Alle vorherigen Vorstandsmitglieder haben ihren Rücktritt erklärt, wodurch der Vorstand auf insgesamt fünf Mitglieder reduziert wurde. Das Unternehmen könnte in den kommenden Monaten die Hinzufügung von Direktoren mit Fachwissen in der klinischen Entwicklung in Betracht ziehen.
Androski erklärte, dass diese Veränderungen in der Führung darauf abzielen, einen "neuen Fokus auf die effiziente Weiterentwicklung der Unternehmenspipeline und die Maximierung der Beiträge des Unternehmens zur LNP-Abliefertechnologie durch Genevant" zu ermöglichen. Das Unternehmen wird vorübergehend die Investorenmeetings aussetzen, während die neue Führung die Entwicklungspläne und strategischen Optionen für die Programme zur Bekämpfung von Hepatitis B überprüft.
- New CEO Lindsay Androski brings 30 years of biotechnology, law, and academic experience
- Complete board restructuring with four new directors appointed
- Leadership changes aim to focus on pipeline advancement and LNP delivery technology
- Company considering adding directors with clinical development expertise
- Temporary pause in investor meetings and conferences
- Strategic review of hepatitis B programs indicates potential changes to development plans
- Complete turnover of board leadership may create transitional challenges
- New leadership lacks continuity with previous management
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company’s Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company’s board of directors.
Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She is currently special counsel at Genevant with responsibilities including LNP litigation.
“I would like to thank Michael McElhaugh and the rest of the board for their service,” said Lindsay Androski, CEO of Arbutus. “Along with Arbutus’s new directors, I am excited to lead the company into its next chapter. We believe these changes in leadership will enable renewed focus on advancing the company’s pipeline efficiently and maximizing the company’s contributions to LNP delivery technology through Genevant, both of which we expect will deliver greater value to shareholders and patients alike.”
In addition to Ms. Androski, four new directors have joined the board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija. In connection with the appointment of these new directors, all members of the existing board of directors have stepped down effective immediately and the board was reduced to five members in total. The Company is considering additional directors with expertise in clinical development and may expand the board in the coming months.
The Company will temporarily pause participation in investor meetings and conferences while the new board and management team reviews development plans and strategic options for its hepatitis B programs.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The company is currently developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV). Through its ownership stake in and license agreement with Genevant, Arbutus is also focused on maximizing opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. For more information, visit www.arbutusbio.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include, but are not limited to, statements about Arbutus’s consideration of additional directors for its board.
Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
FAQ
What leadership changes did Arbutus Biopharma (ABUS) announce on February 25, 2025?
What is Lindsay Androski's background before joining ABUS as CEO?
How will ABUS's leadership changes affect investor relations?
What is the new strategic focus for ABUS following the leadership changes?
How many directors now serve on the ABUS board after the February 2025 restructuring?
